Edison, NJ, United States of America

Yi Zhang

USPTO Granted Patents = 7 

 

Average Co-Inventor Count = 4.4

ph-index = 2

Forward Citations = 12(Granted Patents)


Location History:

  • Cranbury, NJ (US) (2015)
  • Edison, NJ (US) (2015 - 2022)

Company Filing History:


Years Active: 2015-2022

Loading Chart...
Loading Chart...
7 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Yi Zhang

Introduction

Yi Zhang is a prominent inventor based in Edison, NJ (US), known for his significant contributions to the field of biotechnology. With a total of 7 patents to his name, he has made remarkable advancements in cancer treatment through his innovative research.

Latest Patents

Among his latest patents are the "Anti-PD-L1-anti-TIM-3 bispecific antibodies," which relate to heterodimeric antibodies that bind human PD-L1 and human TIM-3. These antibodies may be useful for treating cancer, both alone and in combination with chemotherapy and other cancer therapeutics. Another notable patent is the "Anti-Tim-3 antibodies for combination with anti-PD-1 antibodies," which focuses on antibodies that bind human T-cell immunoglobulin- and mucin-domain-containing protein-3 (Tim-3). This invention may aid in treating solid and hematological tumors in conjunction with anti-human PD-1 antibodies, chemotherapy, and ionizing radiation.

Career Highlights

Yi Zhang has worked with esteemed companies such as Eli Lilly and Company and Vaxinnate Corporation. His work in these organizations has contributed to the development of innovative therapies aimed at improving patient outcomes in oncology.

Collaborations

Some of his notable coworkers include Yiwen Li and Langzhou Song, who have collaborated with him on various projects, enhancing the scope and impact of his research.

Conclusion

Yi Zhang's contributions to the field of biotechnology, particularly in cancer treatment, highlight his role as a leading inventor. His innovative patents and collaborations reflect his commitment to advancing medical science and improving therapeutic options for patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…